Bates Donna M, von Eiff Christof, McNamara Peter J, Peters Georg, Yeaman Michael R, Bayer Arnold S, Proctor Richard A
Department of Medical Microbiology and Immunology, University of Wisconsin Medical School, Madison, Wisconsin 53706, USA.
J Infect Dis. 2003 May 15;187(10):1654-61. doi: 10.1086/374642. Epub 2003 Apr 30.
Small colony variants (SCVs) of Staphylococcus aureus were generated via mutations in menD or hemB, yielding menadione and hemin auxotrophs, respectively, and studied in the rabbit endocarditis model. No differences in the 95% infectious dose occurred between strains with regard to seeding heart valves ( approximately 10(6) cfu) or other target organs. No differences were observed between the response of the hemB mutant to oxacillin therapy and that of the parent strain in any target tissues, and significant reductions in bacterial densities were seen in all tissues (compared with untreated controls). In contrast, oxacillin therapy did not significantly reduce bacterial densities of the menD mutant in either kidney or spleen and significantly reduced densities within vegetations. These data show that SCVs are able to colonize multiple tissues in vivo and that the menD mutation provides the organism with a survival advantage during antimicrobial therapy, compared with its parent strain, in selected target tissues.
通过对menD或hemB进行突变,分别产生了金黄色葡萄球菌的小菌落变异株(SCV),即甲萘醌和血红素营养缺陷型,并在兔心内膜炎模型中进行了研究。在接种心脏瓣膜(约10⁶ cfu)或其他靶器官方面,各菌株之间的95%感染剂量没有差异。在任何靶组织中,hemB突变体对苯唑西林治疗的反应与亲本菌株之间没有观察到差异,并且在所有组织中细菌密度均显著降低(与未治疗的对照组相比)。相比之下,苯唑西林治疗在肾脏或脾脏中均未显著降低menD突变体的细菌密度,而在赘生物中的密度则显著降低。这些数据表明,SCV能够在体内定殖于多个组织,并且与亲本菌株相比,menD突变在抗菌治疗期间为该生物体在选定的靶组织中提供了生存优势。